BioTissue begins skin substitute study:
This article was originally published in Clinica
Executive Summary
German tissue engineering firm BioTissue Technologies has begun an international, multicentre study of its skin cell substitute, BioSeed-S, designed to generate data to support the coverage of the product by health insurance bodies. Professor Wolfgang Vanscheidt, director of the Wound Biology Clinic in Hochenschwand, Germany, and president of the German Wound Healing Association, is heading the study. BioSeed-S is already being marketed globally under an exclusive marketing deal between Freiburg-based BioTissue Technologies and Baxter International.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.